CTOs on the Move

CereVasc

www.cerevasc.com

 
The CereVasc eShuntâ„¢ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cerevasc.com
  • 2120 Commonwealth Avenue Suite 1
    Auburndale, MA USA 02466
  • Phone: N/A

Executives

Name Title Contact Details

Funding

CereVasc raised $44M on 06/09/2020

Similar Companies

Lybradyn Inc

Lybradyn Inc is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioCentriq

BioCentriq was founded in 2018 and is a full service CDMO for cell and gene therapy process development and clinical manufacturing. Our ISO-7 certified GMP clinical manufacturing facility is in Newark, NJ. At this facility, we manufacture autologous and allogeneic cell therapies, gene therapies and provide analytical and quality services across several cell types. We offer viral vector production, cell and viral banking and upstream and downstream processing. Additionally, we have the capabilities to manufacture immunotherapies, including monoclonal antibodies and proteins, and vaccines. Our facilities provide full customer access to work in hybrid teams from tech transfer through GMP clinical production. BioCentriq has a BSL-2 certified process development facility located in South Brunswick, NJ to accelerate scale-up and translation activities. We are vendor and technology agnostic and work with our clients to leverage the optimal technology platform for your product through the development process. In support of our full suite of process development and clinical manufacturing services, the team at BioCentriq offers pre-defined and custom workforce development programs as well as full access to our centers during projects in a unique collaborative approach with our expert scientists to knowledge transfer.

MouldWorks

MouldWorks is a Beulah, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neoleukin

Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.

Kirkegaard and Perry Laboratories

KPL is committed to protecting the privacy of our customers. Our Privacy Policy covers any personal information that KPL.com obtains from you when you use services on our site. We use this information to enhance our services and to make them more